Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)

Abstract

The present invention provides compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, methods for their preparation, methods for their use, and pharmaceutical formulations comprising them.

Description

Pyridinesulfamoyl-substituted benzamides as cytochrome P450 3A4 (CYP3A4) inhibitors This application is based on 35 U.S.C. § 119(e) requirements of U.S. Application Nos. 60 / 720,151 filed September 23, 2005, 60 / 723,115 filed October 3, 2005, filed October 11, 2005 Priority 60 / 725,469, 60 / 762,256, filed January 25, 2006, and 60 / 821,664, filed August 7, 2006, each of which is incorporated herein by reference in its entirety. Background technique The cytochrome P450 (CYP450) enzyme system is responsible for the biotransformation of drugs from active to inactive metabolites that are easily excreted by the body. In addition, the rapid metabolism of certain drugs by the CYP450 enzyme system can significantly alter their pharmacokinetic (PK) properties and can lead to subtherapeutic plasma levels of these drugs over time. In the field of anti-infective therapy, such as in the treatment of viral infections, such as human immunodeficiency virus (HIV) infection, such subtherapeutic dr...

AI Technical Summary

Problems solved by technology

However, RTV is associated with clinically significant gastrointestinal and metabolic side effects, including nausea, vomiting, diarrhea, and dyslipidemia

Images